Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies

NCT05797233 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

58

Enrollment

NIH

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
B-Cell Chronic Lymphocytic Leukemia
Lymphoma, B-Cell

Interventions

BIOLOGICAL: Anti-CD19 and anti-CD20 bicistronic CAR T- cells
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

National Cancer Institute (NCI)